| TARA Stock | | | USD 5.26 -0.06 -1.13% |
Use the math operators workspace to apply Price Series Multiplication operator and other studies to Protara Therapeutics and Prelude Therapeutics. The focus on relative price relationships between Protara Therapeutics and Prelude Therapeutics helps organize trend, volatility, and risk context for Protara Therapeutics and Prelude Therapeutics.
Most technical analysis of Protara Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Protara from various momentum indicators to cycle indicators. When you analyze Protara charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara Therapeutics, Inc. is headquartered in New York, New York. Artara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. As a small-cap equity, Protara Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 2.32. Protara Therapeutics has a market cap of 300.09 M, ROE of -31.6%.
Methodology
Unless otherwise specified, financial data for Protara Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Protara (USA Stocks:TARA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Protara Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Protara Therapeutics is covered by 8 analysts. 4 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Tracking Protara Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.